These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31119966)

  • 21. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment.
    Merdin A; İskender D; Ulu BU; Doğan M; Çakar MK; Dal MS; Altuntaş F
    Medicine (Baltimore); 2019 Jul; 98(30):e16482. PubMed ID: 31348254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
    Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
    Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
    Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
    Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.
    Azzoli CG; Patel JD; Krug LM; Miller V; James L; Kris MG; Ginsberg M; Subzwari S; Tyson L; Dunne M; May J; Huntington M; Saunders M; Sirotnak FM
    J Thorac Oncol; 2011 Nov; 6(11):1915-22. PubMed ID: 21841501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma.
    O'Connor OA; Ko BS; Wang MC; Maruyama D; Song Y; Yeoh EM; Manamley N; Tobinai K
    Blood Adv; 2024 Jun; 8(11):2601-2611. PubMed ID: 38429077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial.
    Park S; Kim AY; Cho H; Baik D; Lee H; Cho S; Kang HY
    BMC Cancer; 2020 Nov; 20(1):1157. PubMed ID: 33243162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
    Mould DR; Sweeney K; Duffull SB; Neylon E; Hamlin P; Horwitz S; Sirotnak F; Fleisher M; Saunders ME; O'Connor OA
    Clin Pharmacol Ther; 2009 Aug; 86(2):190-6. PubMed ID: 19474785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.
    Shimanovsky A; Dasanu CA
    Expert Opin Pharmacother; 2013 Mar; 14(4):515-23. PubMed ID: 23409799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis.
    Zhu J; Yeoh EM; Maeda Y; Tobinai K
    Leuk Lymphoma; 2020 Sep; 61(9):2145-2152. PubMed ID: 32536233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4-positive peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma: A post-marketing surveillance in Japan.
    Ishitsuka K; Yasukawa T; Tsuji Y
    Hematol Oncol; 2024 Jul; 42(4):e3292. PubMed ID: 38847317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical remission of primary aggressive CD8+ cutaneous T-cell lymphoma after pralatrexate infusion.
    Kerdel FA; Styperek AR; Maini A
    JAMA Dermatol; 2014 Mar; 150(3):320-2. PubMed ID: 24452280
    [No Abstract]   [Full Text] [Related]  

  • 32. Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin.
    Kitazume K; Akagawa Y; Wada S; Suzuki T; Fujita A
    Case Rep Oncol; 2019; 12(2):529-536. PubMed ID: 31427947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma.
    Kawai H; Ando K; Maruyama D; Yamamoto K; Kiyohara E; Terui Y; Fukuhara N; Miyagaki T; Tokura Y; Sakata-Yanagimoto M; Igarashi T; Kuroda J; Fujita J; Uchida T; Ishikawa T; Yonekura K; Kato K; Nakanishi T; Nakai K; Matsunaga R; Tobinai K
    Cancer Sci; 2021 Jun; 112(6):2426-2435. PubMed ID: 33792128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
    Foss F; Horwitz SM; Coiffier B; Bartlett N; Popplewell L; Pro B; Pinter-Brown LC; Shustov A; Furman RR; Haioun C; Koutsoukos T; O'Connor OA
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):238-43. PubMed ID: 22542448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate.
    Sekiguchi Y; Wakabayashi M; Takizawa H; Iizuka H; Sakajiri S; Sugimoto K; Inano T; Fukuda Y; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Komatsu N; Noguchi M
    J Clin Exp Hematop; 2020; 60(1):26-28. PubMed ID: 32224563
    [No Abstract]   [Full Text] [Related]  

  • 36. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
    Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
    J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.
    Bhurani M; Admojo L; Van Der Weyden C; Twigger R; Bazargan A; Quach H; Zimet A; Coyle L; Lindsay J; Radeski D; Hawkes E; Kennedy G; Irving I; Gutta N; Trotman J; Yeung J; Dunlop L; Hua M; Giri P; Yuen S; Panicker S; Moreton S; Khoo L; Scott A; Kipp D; McQuillan A; McCormack C; Dickinson M; Prince HM
    Leuk Lymphoma; 2021 Feb; 62(2):330-336. PubMed ID: 33026266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
    Marchi E; Raufi AG; O'Connor OA
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.
    Parker T; Barbarotta L; Foss F
    Future Oncol; 2013 Jan; 9(1):21-9. PubMed ID: 23252560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small Primary Cutaneous γδT-Cell Lymphoma Lesions Successfully Treated With Pralatrexate.
    Imataki O; Uchida S; Yokokura S; Uemura M; Kadowaki N
    Clin Nucl Med; 2019 Feb; 44(2):e85-e86. PubMed ID: 30516664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.